ARTICLE

Open Access

Mitochondrial superoxide dismutase 2 mediates γ-irradiation-induced cancer cell invasion

Chan-Hun Jung^{1,2}, Eun Mi Kim¹, Jie-Young Song¹, Jong Kuk Park¹ and Hong-Duck Um¹

Abstract

Sublethal doses of γ -rays promote cancer cell invasion by stimulating a signaling pathway that sequentially involves p53, sulfatase 2 (SULF2), β -catenin, interleukin-6 (IL-6), signal transducer and activator of transcription 3 (STAT3), and Bcl-X_L. Given that Bcl-X_L can increase O₂⁻⁻ production by stimulating respiratory complex I, the possible role of mitochondrial reactive oxygen species (ROS) in γ -irradiation-induced cell invasion was investigated. Indeed, γ -irradiation promoted cell invasion by increasing mitochondrial ROS levels, which was prevented by metformin, an inhibitor of complex I. γ -Irradiation-stimulated STAT3 increased the expression of superoxide dismutase 2 (SOD2), a mitochondrial enzyme that catalyzes the conversion of O₂⁻⁻ to hydrogen peroxide (H₂O₂). In contrast to O₂⁻⁻, H₂O₂ functions as a signaling molecule. γ -Irradiation consistently stimulated the Src-dependent invasion pathway in a manner dependent on both complex I and SOD2. SOD2 was also essential for the invasion of un-irradiated cancer cells induced by upregulation of Bcl-X_L, an intracellular oncogene, or extracellular factors, such as SULF2 and IL-6. Overall, these data suggested that SOD2 is critical for the malignant effects of radiotherapy and tumor progression through diverse endogenous factors.

Introduction

Ionizing radiation (IR), such as γ -irradiation, is a major therapeutic modality for treating cancer. In most patients, IR offers a significant survival benefit, but in some patients, local recurrence or distal metastasis following radiotherapy is a major therapeutic challenge. These undesirable consequences may reflect the regrowth or spread of cancer cells that survived radiotherapy. Studies using cultured cells and animal models have shown that sublethal doses of IR increase the mobility, invasiveness, and metastatic potential of cancer cells^{1,2}, suggesting that IR promotes malignant behavior in postradiation tumors. Therefore, the cellular components involved in the

Correspondence: Hong-Duck Um (hdum@kirams.re.kr)

© The Author(s) 2019

malignant effects of IR should be defined to develop new strategies for improving the therapeutic effects of IR.

Mitochondria have emerged as central regulators of cancer cell invasion and metastasis, and reactive oxygen species (ROS) produced via the mitochondrial respiratory chain have been implicated as stimulators of various cellular pathways leading to cell migration and invasion³. The production of mitochondrial ROS is regulated by Bcl-2 family proteins⁴. Although they were originally identified as key regulators of cell death⁵, certain Bcl-2 family members also regulate cell migration, invasion, and cancer metastasis⁴. A well-characterized example is the group of pro-survival Bcl-2 family members, including Bcl-X_L, Bcl-2, and Bcl-w, which stimulate complex I, a major source of ROS in the mitochondrial respiratory chain, to produce additional ROS. The ROS produced the following overexpression of Bcl-w, or Bcl-X_L promote cell invasion by stimulating Src and its downstream signaling components⁶.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

¹Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea. ²Present address: Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Korea These authors contributed equally: Chan-Hun Jung, Eun Mi Kim

We have previously shown that sublethal doses of IR increase sulfatase 2 (SULF2) expression via the p53 transcription factor⁷. SULF2 is an extracellular sulfatase that modulates the signaling activities of diverse cell surface receptors⁸, and IR-induced SULF2 mediates the pro-invasive activity of IR by stimulating the signaling pathway that sequentially involves β -catenin, interleukin-6 (IL-6), and signal transducer and activator of transcription 3 (STAT3)⁷. STAT3 is a transcription factor that induces Bcl-X_L expression⁹. Consistently, sublethal doses of IR increase the messenger RNA (mRNA) and protein levels of Bcl-X_L in several cancer cell types, and Bcl-X_L knockdown abolishes the pro-invasive activity of IR^{7,10}, suggesting a role for Bcl-X_L in IR-induced cell invasion. These results suggest the involvement of mitochondrial ROS in IR-induced cancer cell invasion. However, this possibility has not been directly addressed.

ROS include free radicals, such as superoxide anion $(O_2^{\bullet-})$ and hydroxyl radical (HO[•]), as well as nonradical molecules, such as hydrogen peroxide (H_2O_2) . Among these free radicals, H₂O₂ has a relatively long half-life and can freely diffuse to induce signaling¹¹. Therefore, it is thought that H_2O_2 is the effector ROS that modulates activities of signaling molecules. However, the mitochondrial respiratory chain produces O₂^{•-} that needs to be converted to H₂O₂ to modulate signaling. Superoxide dismutase (SOD) is a metalloenzyme that catalyzes the conversion of $O_2^{\bullet-}$ to H_2O_2 . In mammals, there are three distinct types of SOD as follows: Cu/ZnSOD (SOD1), MnSOD (SOD2), and extracellular Cu/ZnSOD (SOD3)¹². SOD1 is the major intracellular form of SOD, and it is localized primarily in the cytosol. In contrast, SOD2 is exclusively localized to the mitochondrial matrix. This feature of SOD2 suggests that it may be involved in the conversion of mitochondrial $O_2^{\bullet-}$ to H_2O_2 , thus contributing to cell invasion. Hence, the present study investigated the potential role of SOD2 in IR-induced cell invasion. The possibility was indeed supported by our data. The present findings demonstrated that SOD2 also mediates the invasion of un-irradiated cancer cells induced by upregulation of diverse oncogenic components, supporting the role of SOD2 in tumor progression. Therefore, SOD2 is a potential target for preventing cancer cell invasion following radiotherapy and suppressing tumor progression under diverse conditions.

Materials and methods

Antibodies and recombinant proteins

The following antibodies were used in the present study: anti-SOD2 from Enzo Life Sciences (Farmingdale, NY, USA); anti-IL-6 and anti- β -catenin from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-Bcl-X_L, anti-STAT3, anti-Src, and anti-phospho-Src from Cell Signaling Technology (Danvers, MA, USA); and anti- β -actin from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human IL-6 was purchased from Millipore (Darmstadt, Germany).

siRNA and shRNAs

Small interfering RNA (siRNAs) targeting IL-6 (S7312) and Bcl-X_L (120717) were purchased from Ambion (Austin, TX, USA). siRNAs targeting SOD2 (sc-41655), β -catenin (sc-44275), and STAT3 (sc-29209) as well as lentiviruses expressing small hairpin RNAs (shRNAs) targeting SOD2 (sc-41655-V), Bcl-X_L (sc-43630-V), and SULF2 (sc-63088-V) were obtained from Santa Cruz Biotechnology.

Cell culture, transfection, infection, and treatments

All cell lines used in this study, except for HCT116/ p53^{wt} and HCT116/p53(-/-) colon cancer cells (a generous gift from Dr. Bert Vogelstein), were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI-1640 (A549, H1299, and H460 lung cancer cells) or DMED (MCF-7 breast cancer and HCT116 cells) medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). Expression constructs for SOD2, SULF2, and Bcl-X_L were prepared using the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA). Expression constructs and siRNAs were introduced into cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The transfectants were used for experiments after 48 h of recovery. For long-term gene silencing, cells were infected with lentiviruses containing shRNAs targeting SOD2 in the presence of polybrene $(5 \mu g/mL)$ according to the manufacturer's protocols. Infected cells were selected with puromycin $(2 \mu g/mL)$. For irradiation, cells were exposed to the specified doses of y-rays from a ¹³⁷Cs y-ray source (Atomic Energy of Canada, Chalk River, Canada) at a dose rate of 3 Gy/min. Alternatively, cells were treated with the indicated concentrations of IL-6.

Western blotting

Cell lysates were prepared using previously described methods¹³. Proteins in the lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, electrotransferred onto nitrocellulose membranes (Millipore), and analyzed using the specified antibodies and an ECL detection system (Bio-Rad, Hercules, CA, USA).

RT-PCR and quantitative real-time PCR

Reverse transcription-PCR (RT-PCR) was performed by amplifying complementary DNA (cDNA) in Premix PCR solution (Takara, Shiga, Japan) with SOD2 primers (5'-GGA-AGC-CAT-CAA-ACG-TGA-CTT-3' and 5'-G TG-CTC-CCA-CAC-ATC-AAT-CC-3'). Quantitative real-time PCR was performed using the SYBR Fast Universal qPCR Kit (Kapa Biosystems, Wilmington, MA, USA) and SOD2 primers (5'-GGC-CTA-CGT-GAA-C AA-CCT-GAA-3' and 5'-CTG-TAA-CAT-CTC-CCT-T GG-CCA-3'). *GAPDH* was amplified in both PCR assays with the following primers as an internal control for normalization: 5'-CAT-CTC-TGC-CCC-CTC-TGC-TG A-3' and 5'-GGA-TGA-CCT-TGC-CCA-CAG-CCT-3'. The RT-PCR and real-time PCR results were analyzed by agarose gel electrophoresis and an IQ-5 Real-Time System (Bio-Rad), respectively.

Invasion assay

As described previously¹⁴, cells in serum-free medium were seeded onto the upper surfaces of Matrigel-coated Transwell chambers (BD Biosciences, San Jose, CA, USA). The lower compartments of the chambers were filled with medium supplemented with 10% heat-inactivated FBS. After 16 h of incubation, cells that invaded the lower surface of the filter were stained with the Diff-Quick Kit (Fisher Scientific, Waltham, MA, USA) and counted under a microscope.

Analysis of mitochondrial ROS levels

Cells were exposed to $10 \,\mu$ M MitoSOX Red (Invitrogen) or $5 \,\mu$ M Peroxy Orange-1 (Tocris Bioscience, Bristol, UK) for 30 min, and cell-associated fluorescence was analyzed by flow cytometry.

Clonogenic assay

Various numbers of cells infected with the specified lentiviruses were seeded in triplicate into 60 mm dishes (100, 200, 400, and 800 cells/dish). After 24 h of incubation, cells were exposed to different doses of γ -rays (1, 3, 5, and 7 Gy). Irradiated and untreated control cells were cultured for 14 days. The number of colonies was counted with a colony counter (Imaging Products, Hollywood, CA, USA), and clonogenic survival was calculated as described previously¹⁵.

Statistical analysis

All experiments were performed at least three times to obtain means and standard deviations. Statistical significance was determined with one-way analysis of variance (GraphPad Software, La Jolla, CA, USA), and p values <0.05 were considered significant.

Results

Sublethal doses of IR increase SOD2 expression via the p53/SULF2/ β -catenin/IL-6/STAT3 pathway

To investigate the potential involvement of SOD2 in IRinduced cell invasion, p53^{wt}-expressing (H460 and A549 lung cancer cells as well as HCT116 colon cancer cells) and p53^{null} cells (H1299 lung cancer cells) were irradiated with sublethal doses of γ -rays. Irradiation elevated protein levels of SOD2 in the p53^{wt}-expressing cells but not in the p53^{null} cells (Fig. 1a). Consistently, knockout of p53 in HCT116 cells abolished IR-induced SOD2 accumulation. It has been previously confirmed that p53 protein levels in p53^{wt}-expressing cells are elevated upon γ -irradiation, but that p53 expression is not detected in p53^{null} or p53knockout cells even after γ -irradiation^{16–18}. These findings suggested that the γ -irradiation mediated increase in SOD2 levels is p53 dependent.

p53 mediates IR-induced cell invasion by stimulating cellular pathways sequentially involving SULF2, β-catenin, IL-6, and STAT3⁷. To investigate the relationship between this pathway and SOD2 induction, SULF2 was knocked down in H460 and A549 cells using a specific shRNA, which abolished or attenuated IR-induced SOD2 accumulation (Fig. 1a). Consistently, SOD2 protein levels were increased following overexpression of SULF2 in unirradiated cells (Fig. 1b), confirming that SULF2 increases SOD2 protein levels. Moreover, knockdown of β-catenin, IL-6, or STAT3 using specific siRNAs reduced IR-induced accumulation of SOD2 protein (Fig. 1c), suggesting that IR increases SOD2 levels via the p53/SULF2/β-catenin/IL-6/STAT3 pathway.


In addition, IR elevated mRNA levels of SOD2, and this increase was abolished by knockdown of SULF2 (Fig. 1d) or STAT3 (Fig. 1e), suggesting that IR induces SOD2 protein accumulation by increasing its mRNA levels via STAT3 stimulated by the SULF2 pathway. The ability of STAT3 to induce SOD2 gene expression has also been reported in a mouse model of ischemic brain injury¹⁹. Moreover, the promoter region of SOD2 has been shown to contain STAT3-binding sites¹⁹.

SOD2 mediates IR-induced cell invasion

To investigate the potential role of SOD2 in IR-induced cell invasion, SOD2 was overexpressed in H460 and A549 cells. The invasiveness of both cell lines was enhanced by SOD2 overexpression (Fig. 2a). Consistently, IR-induced cell invasion was reduced by knockdown of SOD2 (Fig. 2b), suggesting that SOD2 mediates IR-induced cell invasion. Consistent with the role of SOD2, its knockdown also abolished cell invasion induced by SULF2 overexpression (Fig. 2c) or IL-6 treatment (Fig. 2d).

IR induces activation of the mitochondrial ROS/Srcdependent invasion pathway


In response to IR, STAT3 increases the mRNA and protein levels of Bcl- X_L , which is essential for IR-induced cell invasion¹⁰. To eliminate the possibility of Bcl- X_L influencing SOD2 expression, Bcl- X_L was overexpressed in H460 cells. Bcl- X_L overexpression did not significantly affect SOD2 mRNA and protein levels (Fig. 3a), confirming the irrelevance of Bcl- X_L in SOD2 induction. These data



expression was compared by RT-PCR using GAPDH as a loading control. **b** A549 and H460 cells were transfected with an empty or SULF2 expression vector, and SOD2 protein and SULF2 mRNA levels were compared. **c** H460 cells treated with a control or an siRNA targeting β-catenin, IL-6, or STAT3 were irradiated with 2 Gy of γ-rays, and the levels of the indicated proteins were compared. **d** H460 cells infected with the lentiviruses indicated in **a** were irradiated, and SOD2 mRNA levels were analyzed by RT-PCR. **e** H460 cells treated with a control or a STAT3-targeting siRNA were irradiated, and SOD2 mRNA levels were compared by quantitative real-time PCR at 24 and 48 h after irradiation

suggested that STAT3 promotes the expression of Bcl-X_L and SOD2 in response to γ -irradiation. Notably, these two proteins co-accumulated at 24 and/or 48 h postradiation (Fig. 3b). This phenomenon was observed in four different p53^{wt} cancer cell lines, including lung (H460 and A549), colon (HCT116/p53^{wt}), and breast cancer cells (MCF-7), and the post-irradiation peak accumulation time was cell type-dependent. The co-induction of Bcl-X_L and SOD2 implied their cooperation in IR-induced cellular responses.

Bcl-X_L overexpression increases the ability of complex I to produce ROS, which, in turn, stimulates the Src-dependent invasion pathway⁶. Given that IR upregulates Bcl-X_L¹⁰, it may also stimulate the ROS/Src pathway. Because complex I produces $O_2^{\bullet-}$, the levels of mitochondrial $O_2^{\bullet-}$ levels in control and irradiated cells were compared using MitoSox Red, a probe specific for mitochondrial $O_2^{\bullet-}$. IR increased mitochondrial $O_2^{\bullet-}$ levels, which was prevented by *N*-acetylcysteine (NAC), an ROS




scavenger, or metformin, an inhibitor of complex I²⁰ (Fig. 3c), suggesting that complex I contributes to IRinduced $O_2^{\bullet-}$ production. IR also increased Src phosphorylation, and both IR-induced cell invasion and Src phosphorylation were abolished by NAC or metformin (Fig. 3d). Similar effects on IR-induced Src phosphorylation were observed following Bcl-X_L knockdown (Fig. 4a, left). These results suggested that $O_2^{\bullet-}$ produced by the Bcl-X_L/complex I pathway contributes to the ability of IR to promote the Src-dependent invasion pathway.

SOD2 mediates IR-induced Src phosphorylation in a cooperative manner with $Bcl-X_L$

While complex I produces $O_2^{\bullet-}$, H_2O_2 is the ROS that stimulates Src phosphorylation²¹. Therefore, SOD2 may mediate IR-induced cell invasion by converting $O_2^{\bullet-}$ to H_2O_2 . IR-induced Src phosphorylation was attenuated by SOD2 knockdown (Fig. 4a, right). SOD2 knockdown also abolished Bcl-X_L-induced cell invasion (Fig. 4b, left), a result consistent with the view that SOD2 acts

downstream of Bcl-X_L to promote cell invasion. However, cell invasion induced by SOD2 overexpression was also prevented by Bcl-X_L knockdown (Fig. 4b, right), suggesting that SOD2 requires Bcl-X_L for cell invasion. The functional interdependence of Bcl-X_L and SOD2 supports the view that both $O_2^{\bullet-}$ production (by Bcl-X_L) and its conversion to H₂O₂ (by SOD2) are critical for cell invasion. The functional cooperation between Bcl-X_L and SOD2 was further supported by the finding that over-expression of both Bcl-X_L and SOD2 was superior to overexpression of either alone for inducing Src phosphorylation and cell invasion (Fig. 4c).

To directly confirm the role of SOD2 in the conversion of IR-induced $O_2^{\bullet-}$ to H_2O_2 , the levels of $O_2^{\bullet-}$ and H_2O_2 were determined using MitoSox Red and Peroxy Orange- 1^{22} , respectively. SOD2 knockdown increased the amount of $O_2^{\bullet-}$ and decreased H_2O_2 levels in both control and irradiated cells (Fig. 4d). Consistently, SULF2 overexpression and IL-6 treatment increased H_2O_2 levels, and this increase was prevented by SOD2 knockdown




(Fig. 4e). Therefore, these findings clearly demonstrated that SOD2 contributes to the conversion of $O_2^{\bullet-}$ generated via the IR-induced SULF2/IL-6 pathway to H_2O_2 .

SOD2 promotes cell invasion without altering radiosensitivity

SOD2 contributes to radioresistance in certain but not all cell types^{23,24}. Colony-forming assays revealed that SOD2 knockdown did not significantly influence the radiosensitivity of H460 and A549 cells (Fig. 5). However, IR-induced cell invasion was inhibited by SOD2 knockdown (Fig. 2b), suggesting that SOD2 mediates IR- induced cell invasion without altering cellular radiosensitivity.

Discussion


In the present study, overexpression or knockdown SOD2 in lung cancer cells showed that SOD2 promotes cancer cell invasion. As similar results have been reported for other types of cancer, such as fibrosarcoma²⁵, salivary²⁶, and tongue carcinomas^{27,28}, the pro-invasive activity of SOD2 appears to be a common feature of diverse cancers. This view is consistent with the report that SOD2 is upregulated in many cancer types, including




lung, breast, colon, brain, thyroid, gastric, and salivary cancers, and especially late-stage metastatic cancers¹². SOD2 upregulation in cancer cells has been correlated with distant metastasis, poorer prognosis, and lower overall and disease-free survival^{12,28}. Therefore, SOD2 upregulation is critical for tumor progression.

An important finding of the present study was that SOD2 functions as a key mediator of IR-induced cancer cell invasion, which was initially indicated by the finding that SOD2 mRNA and protein levels were elevated in cancer cells that survived γ -irradiation. In addition, the ability of IR to increase SOD2 expression has been reported in human fibroblasts²⁹ as well as in mouse brain and gut³⁰. In the present study, the IR-induced SOD2 expression was mediated by the p53/SULF2/β-catenin/IL-6/STAT3 pathway, which has been previously shown to

mediate IR-induced cancer cell invasion⁷. Moreover, prevention of IR-induced cancer cell invasion by SOD2 knockdown directly supports the role of SOD2 in the malignant effects of sublethal doses of IR. This finding and our previous findings^{7,10} demonstrate that IRstimulated STAT3 promotes cancer cell invasion by inducing the expression of SOD2 and Bcl-X_L. Based on the recent report that Bcl-X_L upregulation increases the ability of complex I to produce ROS, which then stimulate the Src-dependent invasion pathway⁶, the ability of IR to utilize the mitochondrial pathway and promote cancer cell invasion was investigated. The findings demonstrated that IR increased mitochondrial ROS production and Src phosphorylation. Notably, ROS production, Src phosphorylation, and IR-induced cell invasion were prevented by treatment with an ROS scavenger (NAC) or a complex



I inhibitor (metformin), thereby supporting the view that IR stimulates the Src-dependent invasion pathway by promoting complex I-dependent ROS production. Thus, SOD2 likely supports IR-induced cell invasion by converting $O_2^{\bullet-}$ generated by complex I to H_2O_2 , a signaling molecule that stimulates Src phosphorylation²¹, which was supported by the finding that SOD2 knockdown abolished IR-induced Src phosphorylation. Similar effects were observed when Bcl-X_L was knocked down, indicating that both Bcl-X_L and SOD2 are required for IRmediated induction of the Src-dependent invasion pathway. Thus, IR-induced Bcl-X_L may increase the ability of complex I to produce $O_2^{\bullet-}$, which is then converted to H_2O_2 by SOD2 (Fig. 6). The ability of SOD2 to convert IR-induced $O_2^{\bullet-}$ to H_2O_2 was further confirmed by determining levels of O2. and H2O2 using specific dyes, namely, MitoSox Red and Peroxy Orange-1, respectively. According to the present model, SOD2 acts downstream of Bcl-X_L in an IR-induced signaling pathway, leading to cell invasion. However, despite this hierarchy, the functional relationship of Bcl-X_L and SOD2 was cooperative. Both Bcl-X_L and SOD2 were required to promote cell invasion, and their co-expression induced Src phosphorvlation and cell invasion much more effectively than either alone, suggesting that both O₂^{•-} production and its conversion to H₂O₂ are required for the pro-invasive activity of IR. The present data also suggested that IR fulfils these two requirements by co-inducing Bcl-X_L and SOD2 via STAT3. This co-induction was verified in lung, colon, and breast cancer cells. Therefore, the model depicted in Fig. 6 is a general mechanism applicable to diverse cancer types.



The ability of p53 to induce SOD2 expression has been reported by other investigators^{31,32}. Although the consensus p53-binding sequences have been identified in the promoter region of SOD2³¹, they are not required for the transcriptional activation of SOD2 by p53³², suggesting that p53 induces SOD2 expression indirectly, which is consistent with the present model (Fig. 6).

Some investigators have reported that SOD2 protects cells from IR²³, while others have reported that SOD2 is irrelevant in radioresistance²⁴. While the reason for this discrepancy is still unclear, the present study demonstrated that SOD2 did not significantly influence the radiosensitivity of H460 and A549 cells. Considering that SOD2 plays an essential role in the IR-induced invasion of H460 cells, it is clear that SOD2 mediates IR-induced cell invasion without altering cellular radiosensitivity.

The present data also suggested that the pro-invasive role of SOD2 is not restricted to extrinsic treatments, such as radiotherapy, as it was also involved in intrinsic factor-induced cell invasion. In the present study, SOD2 was essential for cell invasion induced by Bcl-X_L, an oncogene upregulated in many cancers⁴. In addition, SOD2 mediated cell invasion induced by extracellular factors, such as IL-6 and SULF2, suggesting that SOD2 plays an essential role in cell invasion induced in response to tumor microenvironment changes. Thus, SOD2 is critical for tumor progression under diverse conditions.

Metformin is a first-line medication for patients with type 2 diabetes because it reduces hyperglycemia by suppressing hepatic gluconeogenesis³³. However, accumulating evidence has supported the potential of

metformin for cancer therapy. Metformin has been shown to inhibit the growth of many cancer types³⁴, and among cancer patients with diabetes, metformin users show better survival than non-users³⁵. Metformin also improves tumor responses to radiotherapy by acting as a radiosensitizer³⁶. As metformin is an inhibitor of complex I²⁰, the ability of this drug to disrupt the malignant actions of IR was investigated. This possibility was supported by the finding that metformin suppressed the ability of IR to increase mitochondrial ROS production, Src phosphorylation, and cellular invasiveness. The present findings supported the view that metformin may improve the therapeutic effects of IR not only by acting as a radiosensitizer but also by preventing malignant actions of IR.

In conclusion, the present study showed that SOD2 is a key mediator of IR-induced cancer cell invasion, thereby supporting the critical role of mitochondria in cancer cell invasion and metastasis⁴. Considering the short half-life of $O_2^{\bullet-11}$, mitochondrial SOD2 may have an advantage for converting mitochondrial $O_2^{\bullet-}$ to H_2O_2 . Therefore, mitochondrial components may be potential therapeutic targets for overcoming the malignant effects of IR.

Acknowledgements

This work was supported by grants from the National Research Foundation of Korea (2017R1D1A1B03032395 and 2017R1C1B2006273) and the Korea Institute of Radiological and Medical Sciences. This work was also funded by the Ministry of Science and ICT (MSIT), Republic of Korea (50531-2018).

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 5 April 2018 Revised: 4 September 2018 Accepted: 4 October 2018.

Published online: 12 February 2019

References

- Fujita, M., Yamada, S. & Imai, T. Irradiation induces diverse changes in invasive potential in cancer lines. *Semin. Cancer Biol.* 35, 45–52 (2015).
- Canphausen, K. et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. *Cancer Res.* 61, 2207–2211 (2001).
- Wu, W. S. The signaling mechanism of ROS in tumor progression. *Cancer Metastas. Rev.* 25, 695–705 (2006).
- Um, H. D. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. *Oncotarget* 7, 5193–5203 (2016).
- Delbridge, A. R., Grabow, S., Strasser, A. & Vaux, D. L. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. *Nat. Rev. Cancer* 16, 99–109 (2016).
- Kim, E. M., Park, J. K., Hwang, S. G. & Um, H. D. Src and epidermal growth factor receptor mediate the pro-invasive activity of Bcl-w. *Tumour Biol.* 37, 1245–1252 (2016).
- Jung, C. H. et al. Involvement of SULF2 in γ-irradiation-induced invasion and resistance of cancer cells by inducing IL-6 expression. *Oncotarget* 7, 16090–16103 (2016).

- Hammond, E., Khurana, A., Shridhar, V. & Dredge, K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. *Front. Oncol.* 4, 195 (2014).
- Xiong, A., . & Yang, Z. & Shen, Y. & Zhou, J. & Shen, Q. Transcription factor STAT3 as a novel molecular target for cancer prevention. *Cancers (Basel)* 6, 926–957 (2014).
- Ho, J. N. et al. Bcl-XL and STAT3 mediate malignant actions of gammairradiation in lung cancer cells. *Cancer Sci.* 101, 1417–1423 (2010).
- Rhee, S. G. Redox signaling: hydrogen peroxide as intracellular messenger. *Exp.* Mol. Med. **31**, 53–59 (1999).
- Che, M., Wang, R., Li, X., Wang, H. Y. & Zheng, X. F. S. Expanding roles of superoxide dismutases in cell regulation and cancer. *Drug Discov. Today* 21, 143–149 (2016).
- Jung, C. H. et al. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol. Rep. 29, 2109–2113 (2013).
- Jung, C. H. et al. Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA. *Cancer Lett.* 335, 270–277 (2013).
- Cho, H. J. et al. Luteolin acts as a radiosensitizer in non-small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/ caspase cascade. *Int. J. Oncol.* 46, 1149–1158 (2015).
- Kim, E. M. et al. Thep53/p21 complex regulates cancer cell invasion and apoptosis by targeting Bcl-2 family proteins. *Cancer Res.* **77**, 3092–3100 (2017).
- 17. Kim, E. M., Kim, J. & Um, H. D. Bcl-2 protein targeting by the p53/p21 complexresponse. *Cancer Res.* **78**, 2772–2774 (2018).
- Essmann, F. et al. Irradiation-induced translocation of p53 to mitochondria in the absence of apoptosis. J. Biol. Chem. 280, 37169–37177 (2005).
- Jung, J. E., Kim, G. S., Narasimhan, P., Song, Y. S. & Chan, P. H. Regulation of Mnsuperoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral ischemia. *J. Neurosci.* 29, 7003–7014 (2009).
- Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. *eLife* 3, e02242 (2014).
- Zhuang, S. & Schnellmann, R. G. H₂O₂-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells. *Am. J. Physiol. Ren. Physiol.* **286**, F858–F865 (2004).
- Hong, Y., Li, L., Luan, G., Drlica, K. & Zhao, X. Contribution of reactive oxygen species to thymineless death in *Escherichia coli. Nat. Microbiol.* 2, 1667–1675 (2017).
- Motoori, S. et al. Overexpression of mitochondrial manganese superoxide dismutase protects against radiation-induced cell death in the human hepatocellular carcinoma cell line HLE. *Cancer Res.* 61, 5382–5388 (2001).
- Veldwijk, M. R. et al. Recombinant adeno-associated virus 2-mediated transfer of the human superoxide-dismutase gene does not confer radioresistance on HeLa cervical carcinoma cells. *Radiother. Oncol.* 72, 341–350 (2004).
- Connor, K. M. et al. Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. *Cancer Res.* 67, 10260–10267 (2007).
- Chang, B. et al. SOD2 deregulation enhances migration, invasion and has poor prognosis in salivary adenoid cystic carcinoma. *Sci. Rep.* 6, 25918 (2016).
- Liu, X. et al. Deregulation of manganese superoxide dismutase (SOD2) expression and lymph node metastasis in tongue squamous cell carcinoma. *BMC Cancer* 10, 365 (2010).
- Liu, Z. et al. Manganese superoxide dismutase induces migration and invasion of tongue squamous cell carcinoma via H₂O₂-dependent Snail signaling. *Free Radic. Biol. Med.* 53, 44–50 (2012).
- Akashi, M. et al. Irradiation increases manganese superoxide dismutase mRNA levels in human fibroblasts. Possible mechanisms for its accumulation. J. Biol. Chem. 270, 15864–15869 (1995).
- Veeraraghavan, J., Natarajan, M., Herman, T. S. & Aravindan, N. Low-dose γradiation-induced oxidative stress response in mouse brain and gut: regulation by NFκB-MnSOD cross-signaling. *Mutat. Res.* **718**, 44–55 (2011).
- Hussain, S. P. et al. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. *Cancer Res.* 64, 2350–2356 (2004).
- 32. Dhar, S. K, Xu, Y. & St. Clair, D. K. Nuclear factor kappaB- and specificity protein 1-dependent p53-mediated bi-directional regulation of the

human manganese superoxide dismutase gene. J. Biol. Chem. 285, 9835–9846 (2010).

- Kirpichnikov, D., McFarlane, S. I. & Sowers, J. R. Metformin: an update. Ann. Intern. Med. 137, 25–33 (2002).
- 34. Zi, F. et al. Metformin and cancer: an existing drug for cancer prevention and therapy. *Oncol. Lett.* **15**, 683–690 (2018).
- Sandulache, V. C. et al. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. *Head Neck* 36, 1039–1043 (2014).
- Koritzinsky, M. Metformin: a novel biological modifier of tumor response to radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 93, 454–464 (2015).